


CAPÍTULO REIVINDICATORIO MODIFICADO
(Primer Examen de Fondo)

1. Un compuesto de la Fórmula (IV):



o una sal farmacéuticamente aceptable del mismo, en donde:

cada R^1 se selecciona independientemente del grupo que consiste en alquilo (C_1-C_8), haloalquilo (C_1-C_8), hidroxilo, alcoxi (C_1-C_8), arilo (C_5-C_{12}), heteroarilo de 5 a 12 miembros, cicloalquilo (C_3-C_{10}), heterociclilo de 3 a 12 miembros, OR^4 , SR^4 y $N(R^4)_2$;

R^2 es hidrógeno, halógeno, alquilo (C_1-C_8), hidroxilo, alcoxi (C_1-C_8) o $N(R^5)_2$, en donde cada R^5 es independientemente hidrógeno o alquilo (C_1-C_8), o dos R^5 se unen para formar un anillo heterocíclico de 4 a 6 miembros que contiene 1 a 3 heteroátomos seleccionados de N, O y S;

cada R^3 es independientemente hidrógeno, hidroxilo o NH_2 ; o cuando D es $C(R^3)_2$, R^3 también se selecciona de flúor;

cada R^9 es independientemente hidrógeno o flúor;

D es $C(R^3)_2$, O, o $S(O)_{1-2}$;

B es N o C;

E es NR^1 , CH_2 , $C(R^1)_2$, O, o $-S(O)_2$;

cada R^8 está ausente o se selecciona independientemente del grupo que consiste en alquilo (C_1-C_8), haloalquilo (C_1-C_8), hidroxilo, alcoxi (C_1-C_8), arilo (C_5-C_{12}), heteroarilo de 5 a 12 miembros, cicloalquilo (C_3-C_{10}), heterociclilo de 3 a 12 miembros, OR^4 , SR^4 , $N(R^4)_2$, CN, halógeno y $CON(R^4)_2$, en donde dos R^8 se unen opcionalmente para formar un anillo

espiro-cicloalquilo de 4 a 6 miembros, un anillo fusionado a cicloalquilo, o un puente alquilenos, y en donde dos R^8 se unen opcionalmente para formar carbonilo;

cada R^4 es independientemente $A-R^{14}$, en donde A está ausente, es alquilo (C_1-C_3), $-C(O)-$ o $-SO_2-$, y R^{14} es hidrógeno, alquilo (C_1-C_8), arilo (C_5-C_{12}), heteroarilo de 5 a 12 miembros, cicloalquilo (C_3-C_{10}) o heterociclilo de 3 a 12 miembros, o dos R^4 se unen para formar un anillo heterocíclico de 4 a 6 miembros que contiene 1 a 3 heteroátomos seleccionados de N, O y S;

Q está ausente o es una porción divalente seleccionada de O, S, NH y alquilenos (C_1-C_8);

V es N o C, en donde, si V forma un enlace doble, V es carbono;

W es N o C, en donde, si W forma un enlace doble, W es carbono;


X es N o C, en donde, si X forma un enlace doble, X es carbono;

Y es CR^{10} , N, NR^{10} , O o S, en donde cada R^{10} se selecciona independientemente de hidrógeno, alquilo (C_1-C_8), hidroxilo, alcoxi (C_1-C_8), halógeno, SH, S-alquilo (C_1-C_8) y $N(R^{11})_2$ si Y es CR^{10} , en donde Y forma un enlace doble con un miembro del anillo adyacente cuando Y es CR^{10} o N, y en donde cada R^{11} es independientemente hidrógeno, alquilo (C_1-C_8), arilo (C_5-C_{12}) o heteroarilo de 5 a 12 miembros, o dos R^{11} se unen para formar un anillo heterocíclico de 4 a 6 miembros que contiene 1 a 3 heteroátomos seleccionados de N, O y S, o Y es $C(R^{10})_2$, y los dos R^{10} y el carbono al que están asociados forman un carbonilo o un tiocarbonilo;

Z es CR^{12} , N, NR^{12} , O o S, en donde cada R^{12} se selecciona independientemente de hidrógeno, alquilo (C_1-C_8), hidroxilo, alcoxi (C_1-C_8), fluoro, cloro, bromo, SH, S-alquilo (C_1-C_8) y $N(R^{13})_2$, en donde Z forma un enlace doble con un miembro del anillo adyacente si es CR^{12} o N, en donde cada R^{13} es independientemente hidrógeno, alquilo (C_1-C_8), arilo (C_5-C_{12}) o heteroarilo de 5 a 12 miembros, o dos R^{13} se unen para formar un anillo heterocíclico de 4 a 6 miembros que contiene 1 a 3 heteroátomos seleccionados de N, O y S, y en donde Z no es NR^{12} si X es N, V es C, W es C, e Y es CR^{10} , o Z es $C(R^{12})_2$, y los dos R^{12} y el carbono al que están asociados forman un carbonilo o un tiocarbonilo; y


cada ----- es un enlace opcional, en donde no más de dos ----- no adyacentes pueden estar presentes.

2. El compuesto de acuerdo a la Reivindicación 1, que es de Fórmula (III):





o una sal farmacéuticamente aceptable del mismo.

3. El compuesto, o una sal farmacéuticamente aceptable del mismo, de acuerdo con cualquiera de las Reivindicaciones 1 a 2, en donde:




se selecciona de:







4. El compuesto, o una sal farmacéuticamente aceptable del mismo, de acuerdo con la Reivindicación 3, en donde




se selecciona de:




5. El compuesto, o una sal farmacéuticamente aceptable del mismo, de acuerdo con la Reivindicación 4, en donde:




es:






































6. El compuesto, o una sal farmacéuticamente aceptable del mismo, de acuerdo con la Reivindicación 2, en donde:




se selecciona de:









7. El compuesto, o una sal farmacéuticamente aceptable del mismo, de acuerdo con la Reivindicación 6, en donde:




es:




8. El compuesto, o una sal farmacéuticamente aceptable del mismo, de acuerdo con la Reivindicación 7, en donde:




es:




9. Un compuesto de acuerdo con la Reivindicación 1, que es seleccionado de:







,




,




,




,




,




,




,




,




,




,




,







,




,




,




,




,




,















,


















,




,












,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,



,





,



o una sal farmacéuticamente aceptable del mismo.


10. Un compuesto de acuerdo con la Reivindicación 1 seleccionado de:






























o una sal farmacéuticamente aceptable del mismo.











11. Un compuesto de acuerdo con la Reivindicación 1, que es seleccionado de:

































,




,




,




,




,




,




,




,




,





,



,








o una sal farmacéuticamente aceptable del mismo.

12. Un compuesto de acuerdo con la Reivindicación 1, que es (1S,2S,3S,5R)-3-((6-(difluorometil)-5-fluoro-1,2,3,4-tetrahidroisoquinolin-8-il)oxi)-5-(4-metil-7H-pirrolo[2,3-d]pirimidin-7-il)ciclopentan-1,2-diol, que tiene la estructura:



o una sal farmacéuticamente aceptable del mismo.

13. Un compuesto, o una sal farmacéuticamente aceptable del mismo de acuerdo con cualquiera de las Reivindicaciones 1 a 12, en donde la sal se selecciona de sales de acetato, aspartato, benzoato, besilato, bicarbonato/carbonato, bisulfato/sulfato, borato, camsilato, citrato, edisilato, esilato, formiato, fumarato, gluceptato, gluconato, glucuronato, hexafluorofosfato, hibenzoato, clorhidrato/cloruro, bromhidrato/bromuro, yodhidrato/yoduro, isetionato, lactato, malato, maleato, malonato, mesilato, metilsulfato, naftilato, 2-napsilato, nicotinato, nitrato, orotato, oxalato, palmitato, pamoato, fosfato/fosfato de hidrógeno/fosfato de dihidrógeno, sacarato, estearato, succinato, tartrato, tosilato, trifluoroacetato, aluminio, arginina, benzatina, calcio, colina, dietilamina, diolamina, glicina, lisina, magnesio, meglumina, olamina, potasio, sodio, trometamina y zinc.

14. Un compuesto, o una sal farmacéuticamente aceptable del mismo, de acuerdo con la Reivindicación 13, en donde la sal se selecciona de sales de clorhidrato, tosilato y mesilato.

15. Una composición farmacéutica que comprende un compuesto de acuerdo con cualquiera de las Reivindicaciones 1 a 12, o una sal farmacéuticamente aceptable del mismo, y un portador farmacéuticamente aceptable.
